

Kennedy Giulia C
Form 4
March 04, 2019

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Kennedy Giulia C

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [VCYT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
6000 SHORELINE COURT, SUITE 300

(Street)

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2019

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
Chief Scientific & Med Officer

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

SOUTH SAN FRANCISCO, CA 94080

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|-------------------|---|--|-----------------------------------|
| | | | | Code | V Amount or Price | | | |
| Common Stock | 02/28/2019 | | A | (1) | 8,000 | \$ 0 | 17,400 | D |
| Common Stock | 02/28/2019 | | A | (2) | 32,000 | \$ 0 | 49,400 | D |
| Common Stock | 02/28/2019 | | M | | 397 | \$ 10.45 | 49,797 | D |
| Common Stock | 02/28/2019 | | M | | 11,667 | \$ 8.86 | 61,464 | D |
| Common Stock | 02/28/2019 | | M | | 8,749 | \$ 6.45 | 70,213 | D |

Edgar Filing: Kennedy Giulia C - Form 4

| | | | | | | | | |
|--------------|------------|--|---|----------------|---|--------------------------|--------|---|
| Common Stock | 02/28/2019 | | M | 4,166 | A | \$ 5.43 | 74,379 | D |
| Common Stock | 02/28/2019 | | M | 12,396 | A | \$ 9.05 | 86,775 | D |
| Common Stock | 02/28/2019 | | S | 36,075 | D | \$ <u>(3)</u> 20.4168 | 50,700 | D |
| Common Stock | 02/28/2019 | | S | 1,300 | D | \$ <u>(4)</u> 21.2833 | 49,400 | D |
| Common Stock | 02/28/2019 | | F | 813 <u>(5)</u> | D | \$ 0 | 48,587 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | | |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|---|-----------------|--------------|----------------------------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | \$ 20.21 | 02/28/2019 | | A | | 60,000 | | <u>(6)</u> | 02/27/2029 | Common Stock | 60,000 |
| Stock Option (right to buy) | \$ 10.45 | 02/28/2019 | | M | | 397 | | <u>(7)</u> | 09/15/2024 | Common Stock | 397 |
| Stock Option (right to buy) | \$ 8.86 | 02/28/2019 | | M | | 11,667 | | <u>(8)</u> | 03/01/2025 | Common Stock | 11,667 |
| Stock Option (right to buy) | \$ 6.45 | 02/28/2019 | | M | | 8,749 | | <u>(9)</u> | 02/28/2026 | Common Stock | 8,749 |

buy)

Stock

Option
(right to
buy)

\$ 5.43

02/28/2019

M

4,166

(10)

03/14/2026

Common
Stock

4,16

Stock

Option
(right to
buy)

\$ 9.05

02/28/2019

M

12,396

(11)

03/02/2027

Common
Stock

12,39

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|--------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Kennedy Giulia C 6000 SHORELINE COURT SUITE 300 SOUTH SAN FRANCISCO, CA 94080 | | | Chief Scientific & Med Officer | |

Signatures

/s/ Keith Kennedy as
attorney-in-fact

03/04/2019

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock units awarded on February 28, 2019 vest 25% on March 2, 2020 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.
- (2) Restricted stock units awarded on February 28, 2019 vest 25% on February 28, 2021 and 75% on February 28, 2022 subject to continuing employment of the Reporting Person on each vesting date.
- (3) Represents weighted average sales price. Sale prices for the transactions range from \$20.11 to \$21.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- (4) Represents weighted average sales price. Sale prices for the transactions range from \$21.14 to \$21.39. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- (5) The reporting person is reporting the withholding of 813 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,350 Restricted Stock Units granted on March 2, 2018. The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4.
- (6) The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- (7) The option is fully vested and fully exercisable.
- (8) The option becomes exercisable as to 25% of the shares on March 2, 2016, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- (9) The option becomes exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- (10)

Edgar Filing: Kennedy Giulia C - Form 4

The option becomes exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

- (11) The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.